United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - atazanavir sulfate - capsule - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - atazanavir sulfate - capsule - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - atazanavir sulfate - capsule - 300mg

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited - atazanavir as sulfate 150 mg - capsules - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

Israel - English - Ministry of Health

bristol - myers squibb, israel - atazanavir as sulfate - capsules - atazanavir as sulfate 200 mg - atazanavir - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

Singapore - English - HSA (Health Sciences Authority)

bristol-myers squibb (singapore) pte. ltd. - atazanavir sulfate 341.69 mg eqv atazanavir - capsule - 300 mg - atazanavir sulfate 341.69 mg eqv atazanavir 300 mg

Singapore - English - HSA (Health Sciences Authority)

bristol-myers squibb (singapore) pte. ltd. - atazanavir sulfate 170.83 mg eqv atazanavir - capsule - 150 mg - atazanavir sulfate 170.83 mg eqv atazanavir 150 mg

Singapore - English - HSA (Health Sciences Authority)

bristol-myers squibb (singapore) pte. ltd. - atazanavir sulfate 227.77 mg eqv atazanavir - capsule - 200 mg - atazanavir sulfate 227.77 mg eqv atazanavir 200 mg

European Union - English - EMA (European Medicines Agency)

mylan pharmaceuticals limited - atazanavir (as sulfate) - hiv infections - antivirals for systemic use - atazanavir mylan, co-administered with low dose ritonavir, is indicated for the treatment of hiv 1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products.based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 pi mutations). there are very limited data available from children aged 6 to less than 18 years.the choice of atazanavir mylan in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient’s treatment history.

European Union - English - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - atazanavir (as sulfate) - hiv infections - antivirals for systemic use - reyataz capsules, co-administered with low dose ritonavir, are indicated for the treatment of hiv-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products (see section 4.2).based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 pi mutations).the choice of reyataz in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient’s treatment history (see sections 4.4 and 5.1).reyataz oral powder, co-administered with low dose ritonavir, is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected paediatric patients at least 3 months of age and weighing at least 5 kg (see section 4.2).based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors ( 4 pi mutations). the choice of reyataz in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient’s treatment history (see sections 4.4 and 5.1).